title: Vasopressin and sympathetic systems mediate the cardiovascular effects of the GABAergic system in the bed nucleus of the stria terminalis.
abstract: The bed nucleus of the stria terminalis (BST) is an important part of the limbic system. It has been shown that chemical stimulation of the BST elicited cardiovascular depressive and bradycardic responses. It was also demonstrated that GABA is present in the BST, though its role in cardiovascular control is not yet understood. This study was performed to find the effects of GABA receptor subtypes in the BST on cardiovascular responses and to find the possible mechanisms that mediate these responses in urethane-anesthetized rats. Microinjection of muscimol (500 pmol/100 nl), a GABA(A) agonist, into the BST produced a weak unsignificant decrease in the mean arterial pressure (MAP) and heart rate (HR). Injection of bicuculline methiodide (BMI, 100 pmol/100 nl), a GABA(A) antagonist, caused a significant increase in the MAP (41.3+/-5.1 mmHg) as well as in the HR (33.2+/-5.6 beats/min). Injection of two doses (500 and 1000 pmol/100 nl) of phaclofen, a GABA(B) antagonist, produced no significant change in either MAP or HR. Administration (i.v.) of the muscarinic receptor blocker, homatropine methyl bromide had no effect on the magnitude of mean arterial pressure or heart rate responses to BMI. This suggests that the parasympathetic system is not involved in these responses. However, administration (i.v.) of the nicotinic receptor blocker, hexamethonium bromide had no effect on the magnitude of mean arterial pressure response but abolished heart rate response to BMI. This suggests that the sympathetic system is involved in the bradycardic effect of GABA. On the other hand, administration (i.v.) of a selective vasopressin V(1) receptor antagonist abolished the pressor effect of BMI, which indicates that the GABAergic system of the BST decreases the arterial pressure via tonic inhibition of vasopressin release. In summary, we demonstrated, for the first time, that GABA exerts its influence in the BST through the activation of GABA(A), but not GABA(B), receptors that, in turn, tonically inhibit vasopressin release and sympathetic outflow to the heart.
authors.affiliation: Dept. of Physiology, Hormozgan University of Medical Sciences, Bandar-Abbas, Iran.
authors.forename: Masoumeh
authors.initials: M
authors.lastname: Hatam
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Kharazmi
authors.forename: Ali
authors.initials: A
authors.lastname: Nasimi
mesh_terms: D000818:Animals; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects; D018682:GABA Agents / Q000494:pharmacology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D018079:Receptors, GABA / Q000378:metabolism*; D012686:Septal Nuclei / Q000187:drug effects / Q000502:physiology*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*; D014667:Vasopressins / Q000502:physiology*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D018682:GABA Agents; D018079:Receptors, GABA; D014667:Vasopressins; D005680:gamma-Aminobutyric Acid